#USA #San Diego #Type 1 Diabetes #PAL-119 #Paulex Bio

Paulex Bio Secures Fast-Track Grant from NIH

Paulex Bio Inc., a biopharmaceutical enterprise dedicated to enhancing the body's natural insulin production, has recently announced a significant milestone in diabetes treatment. The company received a Fast-Track Small Business Technology Transfer (STTR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a segment of the National Institutes of Health (NIH). This grant is aimed at furthering development for PAL-119, an innovative oral treatment currently in investigational stages, which focuses on regenerating insulin-producing pancreatic beta cells for individuals with Type 1 and Type 2 diabetes.

The grant was awarded following a competitive assessment by peers, marking a major endorsement of the scientific principles underlying the therapy. This funding will enable the preclinical development of PAL-119 and offers a promising route to potential Phase II support, contingent upon satisfying critical project milestones and gaining NIH approval.

Dr. Miguel Sanjuan, Co-Founder and President of Paulex Bio, emphasized the importance of this grant, stating, "The receipt of this competitive NIH grant is validation of the science behind PAL-119 and its potential to address beta cell loss and dysfunction, which is a central issue in both Type 1 and Type 2 diabetes." His vision involves utilizing PAL-119 to shift how diabetes is treated—moving from standard management to a disease-modifying strategy that could rejuvenate insulin production.

Currently, PAL-119 is undergoing a Phase 1/2a clinical trial in Australia (Clinical Trial NCT07901595). This study aims to assess not only the safety and tolerability of the treatment but also the pharmacokinetics and potential pharmacodynamic effects in healthy individuals and adults diagnosed with either Type 1 or Type 2 diabetes. A key focus of this trial includes measuring C-peptide levels to track endogenous insulin production.

What is PAL-119?

PAL-119 represents a novel dual-action oral small molecule designed for beta cell regeneration. This promising therapy stems from extensive research conducted at the Icahn School of Medicine at Mount Sinai. Targeting a specific enzyme known as DYRK1A, which inhibits beta cell replication, PAL-119 strives to enhance the natural regenerate ability of these crucial cells. Additionally, laboratory studies suggest that PAL-119 can positively influence beta cell functionality via protein kinase A (PKA) signaling pathways that facilitate glucose detection and insulin release.

Significantly, PAL-119 was engineered with enhanced selectivity focusing directly on its intended target and minimized interaction with other regions, which is a notable improvement over previous compounds such as harmine.

Paulex Bio’s Mission

As an innovative biopharmaceutical firm, Paulex Bio Inc. aims to revolutionize diabetes care by addressing the fundamental biological causes that provoke the condition. Its pioneering candidate, PAL-119, stands at the forefront of this mission, with aspirations to efficiently regenerate and restore insulin-producing beta cells. Paulex holds exclusive global rights to PAL-119 and related compounds from the Icahn School of Medicine at Mount Sinai, alongside protection through multiple patent families.

In summary, Paulex Bio’s receipt of the NIH Fast-Track grant marks a pivotal moment in the company’s journey to potentially transform diabetes treatment. With continued research and robust clinical trials, PAL-119 may provide a new beacon of hope for millions affected by diabetes, offering a pathway not just for management, but for regenerative healing at a cellular level. For more insights and updates, interested parties can visit Paulex Bio's official website.